GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
702
c/cagrilintide·posted 1 year ago by u/noor_vermeulen

small win: REDEFINE stopped being a problem at week 21

Lab Clean Column ×2

Quick one. Canada here.

CagriSema works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given advice that simply does not apply outside the US.

Specifics: the route I used took 11 weeks and cost roughly what I expected. The admin was worse than the cost. The thing that would have saved me the most time was knowing which document to ask for at the start.

Happy to answer questions from anyone in the same jurisdiction.

1,076 up / 374 down74% upvoted59 commentsid 1bkamf7 Dec 2024

59 comments

23 in this archive, depth 4

best — the order this archive was captured in

u/emil_agyeman137 points·1 year ago

The satiety on amylin analogs is described as physically different. GLP-1 reduces appetite noise, amylin does co-agonism.

replysharereportpermalink
u/lucia_bruun81 points·1 year ago

amylin is not a GLP-1, posts conflating them get corrected

replysharereportpermalink
u/pavel_halvorsen18 points·1 year ago

Rodent or human data?

replysharereportpermalink
u/noor_vermeulenOP96 points·1 year ago

REDEFINE phase 17 readouts are interesting but 17 person CagriSema is different from 17 trial CagriSema.

replysharereportpermalink
[deleted]43 points·1 year ago

[deleted]

replysharereportpermalink
u/bpc_scepticresearch peptides53 points·1 year ago

the co-agonism question is real and interesting

replysharereportpermalink
u/noor_ivaturi108 points·1 year ago

amylin receptor distribution is different from GLP-1

replysharereportpermalink
u/freya_baptista72 points·1 year ago

amylin receptor distribution is different from GLP-1

Adding to this: REDEFINE is doing more work than the comment implies.

replysharereportpermalink
u/wrong_network_w55 points·1 year ago

CagriSema ratios in trials are fixed, do not extrapolate self-mixing

replysharereportpermalink
u/ines_ekstrom30 points·1 year ago

the mechanism is different, the side effect profile reflects it

replysharereportpermalink
u/lane_map_larrylogistics-5 points·1 year ago

Not convinced. The evidence does not support that reading.

replysharereportpermalink
u/noor_vermeulenOP1 point·1 year ago

This is the "correlation is mechanism" thing again. You changed three variables at once.

replysharereportpermalink
u/amara_kuipers1 point·1 year ago

CagriSema is a fixed combo in trials, not user-mixed

replysharereportpermalink
u/ferritin_low73 points·1 year ago

Strongly agree. REDEFINE is phase 14, not final.

replysharereportpermalink
u/milan_mensah42 points·1 year ago

Yeah, amylin is doing different work than GLP-1.

replysharereportpermalink
u/laila_dumitru40 points·1 year ago

The research community is small on cagrilintide. Forum lore changes faster than data.

replysharereportpermalink
u/lucia_bruun0 points·1 year ago

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

replysharereportpermalink
u/liv_kuipers1 point·1 year ago

That is net peptide content, not purity. Different number, different meaning.

replysharereportpermalink
u/lucia_bruun1 point·1 year ago

Small correction: the trial was 15 weeks, not 15. Does not change your point but people will quote it.

replysharereportpermalink
u/blunt_coldbox1 point·1 year ago·edited

This is correct. The co-agonism is real.

replysharereportpermalink
u/plain_titration28 points·1 year ago

REDEFINE phase 12 readouts are interesting but 12 person REDEFINE is different from 12 trial REDEFINE.

replysharereportpermalink
u/signe_grimaldi13 points·1 year ago

Water content matters more than people think. If a vial is carrying residual moisture, your "10mg" is not 10mg of peptide.

replysharereportpermalink
u/noor_vermeulenOP10 points·1 year ago

the mechanism is different, the side effect profile reflects it

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.